NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 264 filers reported holding NOVOCURE LTD in Q2 2020. The put-call ratio across all filers is 1.62 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $2,432,579 | +74.0% | 33,164 | +80.3% | 0.10% | +65.6% |
Q3 2022 | $1,398,000 | +575.4% | 18,396 | +1867.5% | 0.06% | +916.7% |
Q2 2021 | $207,000 | -96.0% | 935 | -96.9% | 0.01% | -96.7% |
Q4 2020 | $5,138,000 | +47.9% | 29,692 | -4.9% | 0.18% | +16.9% |
Q3 2020 | $3,474,000 | +90.4% | 31,213 | +1.4% | 0.15% | +75.0% |
Q2 2020 | $1,825,000 | -9.5% | 30,782 | +2.8% | 0.09% | -32.8% |
Q1 2020 | $2,017,000 | -90.8% | 29,957 | -88.5% | 0.13% | -87.3% |
Q4 2019 | $22,021,000 | +19.3% | 261,315 | +5.9% | 1.04% | +8.5% |
Q3 2019 | $18,458,000 | -29.1% | 246,835 | -40.0% | 0.95% | -31.6% |
Q2 2019 | $26,029,000 | +36.4% | 411,659 | +3.9% | 1.40% | +28.9% |
Q1 2019 | $19,083,000 | +71.3% | 396,158 | +19.1% | 1.08% | +32.9% |
Q4 2018 | $11,138,000 | -61.3% | 332,667 | -39.4% | 0.81% | -50.9% |
Q3 2018 | $28,785,000 | +74.5% | 549,328 | +4.2% | 1.66% | +58.6% |
Q2 2018 | $16,497,000 | – | 527,055 | – | 1.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |